respiratory syncytial virus Archives

Representative image: Moderna’s early hantavirus vaccine work highlights how mRNA vaccine platforms could support rare-virus preparedness as outbreak-driven concerns renew focus on infectious disease innovation.

Pfizer’s Lyme vaccine showed 73% efficacy, but missed a statistical hurdle. What comes next?

by Pallavi Madhiraju
October 17, 2026
0 Comments

Pfizer will present 57 infectious disease abstracts at IDWeek 2026, including Phase 3 Lyme vaccine findings, new pediatric pneumococcal data and real-world RSV effectiveness studies. The programme highlights pipeline progress while leaving important regulatory and clinical questions unresolved.

A clinician performs a nasal swab beside a compact molecular testing system as AMDI’s sub-10-minute Fast PCR platform targets faster influenza, RSV and COVID-19 diagnosis in urgent-care settings. Representative image.

Medical Devices & Diagnostics

AMDI wins FDA clearance for ten-minute PCR, but can it disrupt point-of-care diagnostics?

by Pallavi Madhiraju
June 20, 2026
0 Comments

Autonomous Medical Devices Incorporated has secured FDA clearance and a CLIA waiver for a four-virus PCR panel, but speed alone may not guarantee widespread adoption.

Pharma & Biotech

How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe

by Pallavi Madhiraju
April 19, 2026
0 Comments

European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.